September 23, 2019
FDA: Class I recall of Allergan Natrelle Biocell textured breast implants
Editor's Note
The Food & Drug Administration (FDA) on September 12 designated the recall by Allergan of its Natrelle Biocell textured breast implants as Class I, the most serious.
The recall was initiated because of a six times higher rate of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a cancer of the immune system, which has been associated with these implants.
Distribution dates are September 14, 2014, to July 24, 2019.
Free Daily News
- Healthcare’s “Blockbuster Moment:” Dr Dan Weberg to deliver opening keynote address at OR Manager Conference
- Hospital staffing report: Nurse turnover eases but vacancies, costs remain high
- Study: Bariatric surgery beats lifestyle changes for patients with cirrhosis, obesity
- CMS vision shifts as agency halts funding for state programs
- Low-cost blood test predicts cardiovascular event risk
- Hospital M&A activity drops to historic low amid economic and policy uncertainty
- GAO urges HHS to improve drug shortage response coordination
- Study: US maternal mortality rises 28% in 5 years, inequities persist
- Routine preop tests catch hidden risks in outpatient cosmetic surgery, Canadian study finds
- Study: Hospital same‑day knee replacements match ASC outcomes, even in higher‑risk patients
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement